SNY Sanofi

By Andrea Figueras

Sanofi said it has seen statistically significant improvement in the trial that examines its cancer drug Sarclisa in combination with carfilzomib, lenalidomide and dexamethasone (KRd).

Results showed a better rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma compared with the use of KRd alone, the French pharmaceutical company said on Monday.

Minimal residual disease negativity is the absence of myeloma cells in the bone marrow after treatment, as measured by diagnostic techniques that must have a sensitivity of at least 1 in 100,000 cells, Sanofi said.

"The safety and tolerability of Sarclisa observed in this trial were consistent with the observed safety profile of Sarclisa in other clinical trials, with no new safety signals observed," it said.

In cases where no cancer cells detected within 100,000 bone marrow cells, the rates of minimal residual disease negativity were of 77% in patients treated with the combination of Sarclisa and KRd, while those who received KRd alone achieved a 67% rate.

The company reported three treatment-related deaths in the Sarclisa combination arm and one in the KRd arm and said that the use of Sarclisa in combination with KRd in this patient population is investigational and hasn't been evaluated by any regulatory authority.

Write to Andrea Figueras at andrea.figueras@wsj.com

(END) Dow Jones Newswires

December 11, 2023 01:35 ET (06:35 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.